For the quarter ending 2025-09-30, XLO made $19,066K in revenue. -$16,287K in net income. Net profit margin of -85.42%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 19,066 | 8,084 | 2,930 | 2,263 |
| Restructuring charges | - | - | - | -41 |
| Research and development | 14,321 | 15,330 | 8,266 | 10,759 |
| General and administrative | 6,674 | 7,120 | 8,515 | 6,307 |
| Total operating expenses | 20,995 | 22,450 | 16,781 | 17,025 |
| Loss from operations | -1,929 | -14,366 | -13,851 | -14,762 |
| Change in fair value of common stock warrant liabilities | 15,380 | 50 | - | - |
| Other income (expense), net | 1,022 | -1,428 | 586 | 742 |
| Total other income (expense), net | -14,358 | -1,478 | 586 | 742 |
| Net loss | - | - | -13,265 | -14,020 |
| Net loss and comprehensive loss | -16,287 | -15,844 | -13,265 | -14,020 |
| Earnings per share, basic | -0.11 | -0.16 | -0.18 | -0.22 |
| Earnings per share, diluted | -0.11 | -0.16 | -0.18 | -0.22 |
| Weighted average number of shares outstanding, basic | 144,106,869 | 96,447,672 | 74,700,364 | 63,465,063 |
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO)